Loading...
01/11 03:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed picture. Financial performance shows modest growth with improved margins and reduced expenses, but concerns about tariffs and competitive pressures weigh negatively. The Q&A section highlights management's unclear responses about tariffs, adding uncertainty. While international sales growth is a positive, the overall sentiment remains cautious due to flat growth in the installed base and operational challenges. Given the absence of strong catalysts or negative surprises, a neutral stock price movement is predicted.
Total Revenue $6,800,000, up 1% compared to Q1 2024.
Global Recurring Revenue $4,700,000, up 1% versus the prior year period.
XTRAC Gross Domestic Recurring Billings $4,100,000, down from $4,600,000 in Q1 2024.
Equipment Revenue $2,100,000, up 1.4% versus Q1 2024.
Gross Profit $3,600,000, up from $3,100,000 in Q1 2024.
Gross Margin 53.5%, up from 45.6% in Q1 2024, driven by efficiency gains and absence of prior inventory write-off.
Total Operating Expenses $5,700,000, down from $6,000,000 in Q1 2024, a reduction of 5% year over year.
Engineering and Product Development Expenses Declined 60% due to reduced headcount and non-recurring consulting expenses.
Selling and Marketing Expenses Declined 1% due to reductions in compensation and consulting expenses.
G&A Expenses Declined 5% due to reduced compensation expenses.
Non-GAAP Adjusted EBITDA Improved by $732,000, marking the best first quarter adjusted EBITDA since Q1 2022.
Cash Burn $749,000, an improvement of roughly $800,000 compared to $1,550,000 in Q1 2024.
Cash Balance $7,800,000, including $1,300,000 of restricted cash related to sales tax audit accrual.
TheraClear X Device Installations: Installed base of 160 TheraClear X devices in the U.S. at the end of Q1 2025, up from 104 devices at the end of Q1 2024.
DTC Strategy: Generated over 1,000 appointments in Q1 2025, with unique patients for insurance benefits up 33% versus Q1 2024.
International Sales Growth: International business achieved $2,500,000 in sales, up 8% year-over-year, with equipment sales up 13% and recurring treatments revenue up 27%.
Operational Efficiency: Gross profit increased to $3,600,000 in Q1 2025, up from $3,100,000 in Q1 2024, resulting in a gross margin of 53.5%.
Cost Reduction: Total operating expenses decreased by 5% year-over-year to $5,700,000.
Elevate360 Consulting Program: Expanded to approximately 100 accounts, focusing on improving device utilization and clinic operations.
Turnaround Strategy: Continued execution of a multifaceted turnaround strategy aimed at increasing recurring revenue per device.
Tariff Impact on International Business: Potential negative impact of tariffs on near-term sales, particularly affecting international revenue. If unresolved, could lead to a significant reduction in international revenue.
Supply Chain Challenges: Mild impact from tariffs on supply chain due to local manufacturing and sourcing. However, suppliers may raise prices due to tariff situations, affecting costs.
Regulatory Issues: Challenges in reimbursement rates and broader indication coverage beyond psoriasis. Working with key opinion leaders and medical associations to expand coverage.
Installed Base Utilization: Flat sequential growth in installed base, with focus on increasing utilization of existing devices while removing underperforming accounts.
Market Competition: Competitive pressures in the dermatology market, necessitating effective strategies to maintain and grow market share.
Operational Challenges: The Elevate360 consulting program requires significant time from sales and clinical staff, indicating potential resource strain during broad expansion.
Turnaround Strategy: Strata Skin Sciences is executing a multifaceted turnaround strategy focused on generating higher recurring revenue per device by optimizing device placements and partnerships.
Elevate360 Consulting Model: The Elevate360 consulting model is being expanded to assist clinics in improving patient conversion and device utilization, showing initial positive results.
Direct to Consumer Marketing: The company is seeing strong performance from its direct to consumer marketing efforts, resulting in increased patient appointments and device utilization.
International Business Growth: International sales reached $2,500,000, up 8% year-over-year, with equipment sales up 13% and recurring treatments revenue up 27%.
TheraClear X Device Growth: The installed base of TheraClear X devices grew to 160, with a 138% increase in patients submitted for reimbursement.
Revenue Expectations: Total revenue for Q1 2025 was $6,800,000, up 1% year-over-year, with recurring revenue also up 1%.
Gross Margin: Gross margin improved to 53.5% in Q1 2025, driven by efficiency gains and absence of prior inventory write-offs.
CapEx Plans: Full deployment of the installed base of TheraClear devices is anticipated by late 2025 or early 2026, with plans to increase CapEx thereafter.
Future Outlook: The company is cautiously optimistic about growth but warns of potential negative impacts from tariffs on international sales.
Patient Growth: The company aims to increase patient treatment numbers significantly, with a focus on converting existing patients into procedures.
Total Revenue Q1 2025: $6,800,000, up 1% compared to Q1 2024.
Global Recurring Revenue Q1 2025: $4,700,000, also up 1% versus the prior year period.
Equipment Revenue Q1 2025: $2,100,000, up 1.4% versus Q1 2024.
Gross Profit Q1 2025: $3,600,000, up from $3,100,000 during the same period in 2024.
Gross Margin Q1 2025: 53.5%, compared to 45.6% for the same period in 2024.
Operating Expenses Q1 2025: $5,700,000, a reduction of 5% year over year.
Cash Balance Q1 2025: $7,800,000, including $1,300,000 of restricted cash.
Common Shares Outstanding: 4,171,161 as of 03/31/2025.
Despite some positive aspects like increased recurring revenue and improved operating expenses, the overall sentiment is negative due to a significant decline in total and equipment revenue, persistent international challenges, and unclear guidance on key metrics like DTC campaign impact. The Q&A revealed management's avoidance of direct answers, which adds uncertainty. The lack of temporary CPT codes for 2026 and tariff impacts further contribute to a negative outlook. The absence of a market cap suggests a potentially stronger reaction, leaning towards a negative stock price movement.
The earnings call summary indicates a decline in total revenue and gross profit, increased operating expenses, and significant cash usage in operations, leading to liquidity concerns. The Q&A section highlights uncertainties around international business due to potential tariffs and ongoing legal issues. Management's reluctance to provide specific guidance further adds to the negative sentiment. Despite the positive impact of the Elevate 360 model, the overall outlook remains negative due to these challenges.
The earnings call summary presents a mixed picture. Financial performance shows modest growth with improved margins and reduced expenses, but concerns about tariffs and competitive pressures weigh negatively. The Q&A section highlights management's unclear responses about tariffs, adding uncertainty. While international sales growth is a positive, the overall sentiment remains cautious due to flat growth in the installed base and operational challenges. Given the absence of strong catalysts or negative surprises, a neutral stock price movement is predicted.
The earnings call summary presents mixed signals. While there are improvements in gross margin, cash flow, and certain revenues, overall revenue growth is minimal. The Q&A reveals concerns about tariffs and unclear management responses, impacting sentiment negatively. The positive factors such as improved cash burn and gross margin are offset by competitive pressures and regulatory issues. Given these mixed results and uncertainties, the stock price reaction is likely to be neutral in the absence of significant catalysts.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
